Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for Simulated Shift Work Disorder
NCT06231641Phase 2Terminated
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lemborexant in shift work sleep disorder (SWSD) (2 arms). Primary endpoints: Total sleep duration (objective measure) and Wake after sleep onset (objective measure). Started Jan 2024; status: terminated.
02
Drugs
lemborexant
03
Conditions
shift work sleep disorder (SWSD)
Beyond the preview
Go deeper on NCT06231641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231641.